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Abstract. Oncolytic virotherapy - the use of viruses that specifically kill tumor
cells - is an innovative and highly promising route for treating cancer. However,
its therapeutic outcomes are mainly impaired by the host immune response to the
viral infection. In the present work, we propose a multiscale mathematical model
to study how the immune response interferes with the viral oncolytic activity. The
model assumes that cytotoxic T cells can induce apoptosis in infected cancer cells
and that free viruses can be inactivated by neutralizing antibodies or cleared
at a constant rate by the innate immune response. Our simulations suggest
that reprogramming the immune microenvironment in tumors could substantially
enhance the oncolytic virotherapy in immune-competent hosts. Viable routes to
such reprogramming are either in situ virus-mediated impairing of CD8+ T cells
motility or blockade of B and T lymphocytes recruitment. Our theoretical results
can shed light on the design of viral vectors or new protocols with neat potential
impacts on the clinical practice.
1. Introduction
Recently, cancer replaced heart disease as the leading cause of death among the
United States citizens younger than 85 years [1] and will probably become the leading
one in some other parts of the world within a few years [2]. In the past decades
we have witnessed an extraordinary progress on imaging, diagnosis, and research in
the molecular biology of cancer, but its medical treatment, especially of tumors at
unresectable locations, metastasis or recurrent neoplasias, still has many limitations
[3]. Even the advent of molecularly targeted therapies has led to modest improvements
for the majority of patients with advanced cancers [4]. Due to the complexity of
tumor growth pathways, increasing resistance and tumor progression still is the rule
for patients with metastatic disease. Hence, new pathway-independent therapeutic
agents represent a central alternative. Among them, oncolytic viruses are unique since
they can be amplified by infected cells, armed to selectively infect and kill cancer cells
and induce an immune response against the tumor [5].
Several oncolytic viruses exhibiting safety and selective replication in tumors are
under current evaluation in pre-clinical and clinical trails [6, 7]. However, durable
objective responses are relatively rare because their in vivo antitumor efficiencies
are mainly impaired by the host immune response [8] that prevents successful virus
spreading and tumor remission [9]. In a clinical context, the therapeutic outcome
is a drastically reduced direct oncolytic activity, much less than those suggested by
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experimental models. Initially, upon virus administration, the innate immunity plays
a significant role in limiting virotherapeutic efficiency [10, 11]. Indeed, in gliomas
treated with herpes simplex viruses (HSV), the recruitment of infiltrating monocytic
cells has been associated with intratumoral clearance of over 80% of HSV-derived
viral particles shortly after delivery [12]. Subsequently, the adaptive immune response
develops and becomes dominant after ∼ 5 days post-infection [13]. This cellular and
humoral immune response involves the recruitment of antigen-specific B cells and
CD8+ T cells to the infected tissue.
As can be noticed, various fundamental issues and technical hurdles must be
understood and overcome in order to enhance the efficacy of oncolytic virotherapy. It
is imperative to enlarge our current understanding concerning the complex and coupled
dynamics of the growing tumor, the host immune response and the oncolytic viruses.
The nonlinearities and complexities inherent to such dynamics call for mathematical
approaches [14, 15]. Quantitative models can reveal the major parameters affecting
therapeutic outcomes, guide new essays by indicating relevant physiological processes
for further investigation, and prevent excessive experimentation needed to develop
effective treatments.
In the present paper, we report on theoretical findings derived from a multiscale
agent-based model for oncolytic virotherapy. Such findings point out implications
for the design of new replication-competent viruses or combined therapy aimed to
modulate the immune response. In section 2, the model is described. It takes explicitly
into account the individual, discrete nature of the oncolytic viruses and includes the
host adaptive immune response against the viruses. In section 3, the simulation results
are discussed. In section 4, current or viable strategies to enhance the virotherapy
efficacy against solid tumors consistent with our simulation results are emphasized.
Finally, some conclusions are drawn in section 5.
2. A multiscale agent-based model for oncolytic virotherapy
The proposed model is an extension of our work on oncolytic virotherapy [16, 17, 18]
and involves multiple agents and processes involved at distinct time and length scales.
2.1. The tissue
The tissue is modeled by a square lattice fed through a single capillary vessel at the top
of the lattice. Six different cell types (normal and dead cells, uninfected and infected
cancer cells, B and CD8+ T lymphocytes) and an oncolytic virus are considered.
Each cell and virus are represented by individual agents and their populations in a
site x = (i, j) described by σn, σd, σ
un
c , σ
inf
c , σB , σT , and σv, respectively. Only one
cell can occupy a given site, except uninfected or infected cancer cells that can pile
up because tumor cell’s division is not constrained by contact inhibition. Antibody
molecules directed against the oncolytic virus are also considered and described by
its concentration A(x). Since the viruses and antibodies are very small particles in
comparison with cells, there is no constraint on their populations or concentrations at
any site.
The nutrients, diffusing from the capillary vessel throughout the tissue, are
divided into two groups: those essential to maintain the basic cell functions, whose
deprivation can induce death (φ1) and those that limit cell replication but are not
demanded for cell survival (φ2). Both nutrient types are described by continuous
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fields φj(x, t), which evolve in space and time accordingly the simplest (linear with
constant coefficients) dimensionless reaction-diffusion equations
∂φj
∂t
= ∇2φj − α2φjσn − λjα2φjσc, (1)
with distinct uptake rates for normal and cancer cells and a characteristic length scale
α for nutrient diffusion [19]. The local populations of normal and cancer cells are
σn = 0 or 1 and σc = σ
un
c + σ
inf
c = 0, 1, 2, . . ., respectively. Equation (1) obeys
a periodic boundary condition along the direction parallel to the capillary and a
Neumann boundary condition at the border of the tissue (i = L). At the capillary
(i = 0), the concentration is φ1,2 = 1 (continuous and fixed supply).
2.2. Cancer growth
The tumor grows from a single malignant cell according to a stochastic dynamics whose
probabilities depend on the local nutrient concentration. Each uninfected cancer cell,
randomly selected with equal chance, can carry out one of four actions:
1- Mitotic replication, with a probability
Pdiv = 1− exp
[
−
(
φ2
θdivσc
)2]
, (2)
an increasing function of the nutrient concentration per cancer cell, φ2. The daughter
cell randomly occupies one of its normal or necrotic nearest neighbor sites, where there
exists any, or otherwise piles up at its mother site.
2- Death, with a probability
Pdel = exp
[
−
(
φ1
θdelσc
)2]
, (3)
that increases with the scarcity of nutrients φ1 essential to sustain the cell metabolism.
3- Migration, with a probability
Pmov = 1− exp
[
−σc
(
φ1
θmov
)2]
, (4)
that increases with the local population of cancer cells and the nutrient concentration
per cell. The migrating cell moves to one of its nearest-neighbor sites chosen at
random, interchanging its position with a normal or dead cell if there exists any.
The interchanged normal cell is eliminated when it arives at a site still occupied by
other cancer cells. A probability increasing with the nutrient concentration is justified
by the necessity of nutrients for cell motility and, in addition, by the degradation
of the extracellular matrix near the tumor surface that releases several chemicals
that promote cell migration and proliferation. This hypothesis is consistent with
experimental data in multicellular tumor spheroids [20] and was previously used in
other mathematical models [21, 22].
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2.3. Oncolytic virotherapy
The virotherapy begins when the tumor attains N0 cells and consists in a single virus
injection. In the direct intratumoral administration, viruses are uniformly spread over
the entire tumor at a given multiplicity of infection (MOI). Thus, N0 ×MOI viruses
are initially released. This approach corresponds to the experimental protocols used
in severe combined immune deficient (SCID) mice [23] and in vitro assays [24, 25].
After virus administration, each uninfected cancer cell, randomly selected with
equal chance, can become infected with a probability
Pinf = 1− exp
[
−
(
σv
σcθinf
)2]
, (5)
an increasing function of the local viral load per cell, controlled by the parameter θinf .
The model assumes perfect viral selectivity for cancer cells, thereby the infection of
normal cells by oncolytic viruses is neglected. The number of viruses nv that infect a
given cell is selected from a Poisson distribution,
P (nv) =
knve−k
nv!
, (6)
where k is the typical viral entry [26]. The model assumes that an infected cancer cell
neither divides nor migrates because its slaved cellular machinery is focused on virus
replication. It is also assumed that infected cancer cells sustain their metabolism until
lysis and die only by lysis. The death by lysis occurs with a probability
Plysis = 1− exp
(
−Tinf
Tl
)
, (7)
where Tinf is the time elapsed since the cell infection and Tl is the characteristic time
for cell lysis. The lysis of each infected cancer cell releases
v0 = bs
nv
ξ + nv
(8)
free viruses to the extra-cellular medium. Here, the maximum virus burst size bs and
ξ are model parameters. At the time of lysis, the new free viruses remain on the site
of the lysed cell. At each time step, these free viruses either spread through the tissue
by performing independent random walks comprising q steps or are cleared at a rate
γv. The clearance rate γv embodies the innate immune responses and non immune
mechanisms of virus inactivation.
2.4. Antiviral immune response
Concerning the adaptive immune response, the model assumes that B and CD8+ T
cells are recruited to the infected tissue if there are more than Nmininf infected cancer
cells within the tumor tissue. At lower infection levels, the signaling is supposed too
weak to induce lymphocyte recruitment, and the populationsNB of B andNT of CD8
+
T lymphocytes will decrease due to their finite lifespans, TB and TT , respectively. The
recruited lymphocytes extravagant from the capillary vessel into the tissue at constant
rates βB and βT , respectively. This is the simplest description of the complex process
of lymphocyte recruitment.
At each time step, NT effector CD8+ T cells randomly selected move inside
surveillance areas of radii RT centered on their present position. In every area free
from infected cancer cells, the chosen T cell jumps at random to a site at its border.
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Otherwise, the cytotoxic T cell jumps randomly to an empty nearest-neighbor site of
an infected cancer cell inside that region. This corresponds to a directed migration
towards the infected region, with either less or more confined trajectories in regions
free or containing infected cancer cells, respectively. These rules are suggested by in
vivo imaging of cytotoxic T cell infiltration in a solid tumor growing subcutaneously
[27]. CD8+ T cells attached to one or more nearest-neighbor, infected cells will induce
the apoptosis of only one of these target cells with a probability Papop. Indeed, the
action of a cytotoxic CD8+ T cell seems to be narrowly focused on just one of its
points of contact with a target cell at once [28]. Again, the target cell to be destroyed
will be chosen at random among these nearest neighbors.
Similarly, every B cell can only move inside a surveillance area of radius RB either
towards a site containing infected cancer cells, or to a border site randomly chosen
in infected cell free regions, where it secrets antibodies at a rate βA. In addition, a
significant amount of these antibodies enter into the systemic circulation and during
the infection sustain a specific antibody concentration in the capillary vessel. The
model assumes that these antibodies infiltrate the infected tissue at a constant rate.
Thus, the antibody concentration is given by a non-stationary solution of the diffusion
equation
∂A
∂t
= DA∇2A+ βAσB − γAA. (9)
Here, DA is the diffusivity and γA the clearance rate of the antibodies. At the capillary,
the boundary condition is A(x, 0) = A0, representing a fixed concentration in the
bloodstream.
The antibodies prevent virus binding to cellular receptors and subsequent cell
entry, neutralizing the virus. We assume that free viruses can be inactivated by
antibodies with a probability
Pintact =
{
2A(i,j)
A(i,j)+Ainact
, if A(i, j) ≤ Ainact
1 , otherwise
(10)
a function of the local antibody concentration that increases monotonicaly up to a
threshold Ainat and saturates at the unity above this concentration. Antibodies are
removed at binding to a free virus in order to inactivate it. We assume that the
local concentration of antibodies decreases by Ainact at each virus neutralizing event.
Finally, the parameter estimates can be found in the appendix.
2.5. Simulation protocol
The simulations were implemented as follows. At each time step, Eq. (1) is numerically
solved in the stationary state (∂φ/∂t = 0) through relaxation methods, and Eq. (A2)
is iterated for a defined number of steps. Then, fractions of free viruses are cleared,
innactivated by antibodies with a probability given by eq. (10), and each remaining
virus performs a random walk with q steps. Provided the nutrient concentration and
viral load at any lattice site, both B and CD9+ T lymphocytes are recruited to the
tissue. So, N1 cancer cells and N2 lymphocytes are sequentially selected at random
with equal probability. (Here, N1 is the total number of tumor cells, uninfected or
infected, and N2 is the number of B and CD8+ T lymphocytes at the time t.) For
each one of them, a tentative action is randomly chosen with equal probability. These
actions are division, death, migration or infection for an uninfected cancer cell, lysis for
an infected tumor cell, movement for a B cell and movement or cytotoxic action for a
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CD8+ T lymphocyte. For a cancer cell, the selected action will be implemented or not
according to the corresponding local probabilities determined by Eqs. (2) to (7). In
the case of infection, an integer random number nv Poissonian distributed is generated
and compared with the local virus population σv. If σv ≥ nv, nv viruses invade the
selected uninfected cancer cell, decreasing σv by nv. Otherwise, this process will be
repeated until generates a nv ≤ σv. In turn, in the case of lysis, v0 new viruses are
introduced at the site of the lysed cell. For a T cell cytotoxic action, the apoptosis of
a nearest-neighbor infected cancer cell is elicited with a probability Papop. At the end
of this sequence of N1 +N2 updates, a new time step starts and the entire procedure
is iterated. The simulations stop if any tumor cell reaches the capillary vessel or the
tissue border or if the tumor is eradicated (Nc = 0).
3. Hurdling the major obstacle: immunity
We simulated the model considering a viral agent able to eradicate compact solid
tumors in the absence of an adaptive immune response, as reported in reference [16].
When applied to immune-competent hosts characterized by typical immunological
parameters (see the Supplementary Information), a virotherapy based on such
oncolytic virus invariably fails. The reason is that free viruses as well as their sources,
the infected cancer cells, are eliminated by the adaptive immune response. Even at
small virus clearance rate, representing a permanent depletion of the innate response,
the adaptive immunity against the oncolytic virus ends to subvert the therapy. As
experimentally observed [12], there occurs only a significant transient increase in
intratumoral viral titers shortly after viral administration. Hence, the central issue
is how to suppress, or better, modulate the adaptive immune response in order to
enhance the success of viral therapies of cancer in immuno-competent hosts.
Our results indicate three routes to enhance the chances of tumor eradication in
immuno-competent patients. In the first one, the recruitment of B cells to the infected
tissue is completely suppressed. The corresponding probabilities of therapeutic success
for different CD8+ T cell surveillance radii are shown in figure 1. The absence of B cells
ensures that the antibody concentration within the tissue remains always below the
level necessary to neutralize the free oncolytic viruses, whereas short-range surveillance
radii make certain that CD8+ T cells reach the tumor at a rate insufficient to eliminate
the infected cancer cells before the successive waves of viruses infect all cancer cells.
In contrast, cytotoxic T cells having a long-range surveillance radius (RT ≥ 300µm)
can induce apoptosis in all infected tumor cells if recruited at rates ≥ 5 cells/h.
Now, the successive rounds of infection are strongly attenuated and the probability of
therapeutic success becomes lower than 15%. Furthermore, the oncolytic virotherapy
fails if the concentration of antibodies at the capillary is very large, as possibly elicited
by a potent systemic immune response. Indeed, the probability of therapeutic success
decreases to about 10% if A0 is tenfold greater and vanishes if A0 is multiplied by
a factor ∼ 103, a concentration corresponding to the levels observed in a secondary
immune response to a previously presented antigen. These results are consistent with
clinical trials and rodent tumor models, which indicate that neutralizing antibodies
against viral antigens significantly impair the therapeutic efficacy of several adenoviral
vectors [6, 13, 29].
The second route consists in suppressing both CD8+ T cells and antibody
infiltration. Thus, only B cells are recruited to the tumor site. In consequence,
the tumor is eradicated with probability higher than 90% (see Figure 2a). This great
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Figure 1. Tumor eradication probability as a function of the CD8+ surveillance
radius. The recruitment of B cells is suppressed (βB = 0) and that of T cells
occurs at a rate βT = 40 (≡ 10h−1). Antibodies infiltrate the tissue from
the capillary, where their concentration is A0. The data correspond to 100
independent simulated samples.
therapeutic success is sustained even for B cells with surveillance radius as large as
RB = 500µm, recruited at rates up to βB = 40h
−1, and synthesizing antibodies at
rates up to two orders of magnitude greater than βA. Our simulations indicate that
B lymphocytes alone can not elicit an effective immune response against the oncolytic
virus. Indeed, B lymphocytes are antibody’s sources in permanent migration. They
do not stay in the neighborhood of any infected cancer cell long enough to increase
sufficiently the local antibody’s concentration to inactivate most of viruses released
after the lysis of this cell. However, if antibodies extravasate from the capillary into
the tissue, the total antibody concentration in the tumor is high enough to inactivate
most of the free viruses, decreasing abruptly the therapeutic success (figure 2b).
Finally, the third scenario for tumor eradication consists in impairing the motility
of both B and T cells without affect the antibody dynamics or lymphocyte recruitment
rates. If the surveillance radii are short-ranged (RB ≤ 100µm and RT ≤ 200µm) the
tumor is eradicated with a probability greater than 70% for lymphocytes recruited at
low rates βB = βT = 5h
−1. In figure 3, the tumor eradication probability is shown for
three distinct recruitment rates. Lymphocytic motility is a much more determinant
feature than its recruitment rate. The key to success is to provide enough time for
the viruses to kill the cancer cells before the infiltrating B and T lymphocytes elicit
an effective antiviral cellular immune response. If a few cancer cells survive the virus
attack until they fall into the surveillance radii of the incoming B and T cells, the
virotherapy fails because the free viruses and infected cancer cells are then quickly
eliminated. This is illustrated in figure 4. As can be noticed, 20 days after viral
administration the tumor undergoes a significant remission and the first lymphocytes
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Figure 2. Tumor eradication probability for increasing B cell surveillance radius.
The recruitment of T lymphocytes is suppressed (βT = 0) and antibodies (a) do
not infiltrate the tissue or (b) extravasate from the capillary into the tissue. The
antibody’s concentration at the capillary A0. B cells are recruited at a rate
βB = 10h
−1. The data correspond to 100 independent simulated samples.
have the tumor inside their surveillance radii. Then, the local adaptive immune
response mediated by B and T cells spends around 2 months to eliminate almost
all free viruses and infected cancer cells, leaving room for tumor regrowth from the
few surviving malignant cells.
4. From theory to the clinical practice
Numerous clinical trials have firmly demonstrated that the efficacy of oncolytic viruses
is drastically reduced by the host antiviral immune response. Accordingly, the
immunossupressor cyclophosphamide, a chemotherapeutic drug which inhibits the
synthesis of neutralizing antibodies [30, 31], IFN-γ [32], and the activity of innate
immune cells [33], is commonly co-administered with HSV [34, 35] and reovirus [7],
abrogating the innate and adaptive humoral immunity. However, instead of a systemic
immunity suppression, our results support that a local, in situ, disruption of the
antiviral response strongly enhances oncolytic virotherapy.
This goal can be achieved through the design of efficient oncolytic viruses. Indeed,
one rationale supported by our simulational results is to arm oncolytic viruses with
genes encoding for inhibitors of chemokines, interleukines, or interferons. Once
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Figure 3. Tumor eradication probability as a function of lymphocyte surveillance
radii. Antibodies infiltrate the tissue from the capillary, where A = A0. The
lymphocytes are recruited at rates (a) βB = βT = 1.25h
−1; (b) βB = βT =
2.5h−1; and (c) βB = βT = 5h−1. The data correspond to 100 independent
simulated samples.
introduced in, expressed and secreted by infected cancer cells up to their lysis, such
inhibitors will actively abrogate the recruitment of lymphocytes, mainly effector CD8+
T cells, to the tumor site. This goal can possible be achieved through diverse
approaches. For instance, by blocking the expression of CXCL9 and CXCL10 in
situ. These chemokines are necessary for cytotoxic T lymphocytes (CTL) to enter
from the systemic circulation into the site of infection [36]. Moreover, the down-
regulation of CXCL9 reduces CD4+ T cell infiltration into the infected tissue [37].
Such local depletion of CD4+ T cells significantly blocks further CTL recruitment,
primarily dependent on the IFN-γ secreted by the CD4+ cells [36]. In turn, lower local
levels of CD4+-derived IFN-γ inhibits the expression of CXCL9 and the autocrine-
mediated conditioning of CD4+ T cells for access to the infected tissue [36], closing a
feedback loop. Even the residual CTL recruitment observed in the absence of CD4+
lymphocytes or IFN-γ can be eliminated through the neutralization of type I IFN,
such as IFN-αβR [36].
Related to this context, one innovative development deserve special emphasis.
the rVsV-gG virus inhibited the chemotaxis of NK and NKT cells to the tumor sites
[38]. This gG viral protein binds C, CC and CXC chemokines with high affinity,
possibly suppressing lymphocytic recruitment in addition to the host inflammatory
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Figure 4. Spatiotemporal patterns of cancer cells, lymphocytes and virus ((a),(b)
and (c)) and related antibody concentrations ((d),(e) and (f)). (a) and (d): the
beginning of the adaptive immune response, 5 days after the virus administration;
(b) and (e): 20 days later. At this time the tumor is almost eradicated. (c)
and (f): 2 months later. The adaptive immune response eliminated almost
all free viruses and infected cancer cells, but the tumor keeps growing. The
values βB = βT = 2.5h
−1 for lymphocyte recruitment rates, RB = 150µm and
RT = 300µm for B and T cells surveillance radius were used. For this parameter
set, the probability of therapeutic success is 30%. The red line in top panels
represents the capillary vessel.
response. Such a possibility remains to be checked. Concerning interleukines, several
groups [39] have reported that vaccinia virus expressing Th2 cytokines such as IL-4
and IL-10 has increased in vivo viral replication and slowed clearance rate. Maybe,
another inspiring case is that of a HSV-1 vector expressing IL-5 able to decrease the
numbers of infiltrating lymphocytes in the brain during the treatment of experimental
autoimmune encephalomyelitis [40].
The second rationale lies on severely constrain the motility of B and T cells
that infiltrate the infected tissue. A possible approach is engineering oncolytic
viruses to encode potent and diffusible products disruptive of migration pathways
targeted to the effector lymphocytes. At the site of infection, the lymphocytes’
adhesion molecules, particularly β2-integrins, turn into highly active states. Again,
this activation is induced by chemokines [41] and Rap1 is a critical mediator of both
β1- and β2-integrin activation, cell polarization as well as cell migration [42]. Thereby,
presumably an oncolytic vector encoding an inhibitor of Rap1 or its effector molecule
RAPL can significantly impair lymphocyte motility. Alternative strategies might
target the lymphocyte’s cytoskeleton. T cells use amoeboid migration based on actin
polymerization along the plasma membrane to stiffen and contract the cell cortex
[43]. Small GTPase RhoA and its effector ROCK critically control the cortical actin
dynamics. Interfering with RhoA and/or ROCK results in a failure of the trailing edge
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to detach, dramatically reducing the migration rate of T cells [44], as well as impairing
acto-myosin contraction required for amoeboid movements. Thus, inhibitors of such
proteins emerge as immediate transgene candidates for virus-mediated suppression
of lymphocytic motility. Other candidate can be, for instance, the Wiskott-Aldrich
syndrome protein (WASP) that plays a pivotal role in regulating surface receptor
signaling to the actin cytoskeleton in hematopoietic cells. Blocking WASP activity
leads to a severe defect in cell migration in multiple cell types [45].
5. Concluding remarks
A fundamental issue concerning the efficiency of the viral therapy of cancer, namely,
the abrogation of the host antiviral immune response, was investigated through
computer simulations of a multiscale model for tumor growth. The model combines
macroscopic diffusion equations for the nutrients and antibodies and stochastic rules
for the actions of individual cells and viruses. Even though current strategies to
improve virotherapeutic efficacy consist in developing viruses that can evade the
adaptive immune response, we propose testable alternatives focused instead on the
local disruption of the cellular-mediated immunity.
Essentially, our results indicate two distinct and complementary routes. The first
one is to halt the recruitment of effector lymphocytes, mainly the CD8+ T cells, at
the tumor-bearing tissue infected with the oncolytic virus. The second approach is
based on strongly reducing the motility of B and T lymphocytes that infiltrate the
affected tissue. We find that the lymphocytes surveillance radii, determining both
their motility and targeting ability, rather than their recruitment rates, are the major
immunological features to be modulated. Hence, the second route seems to be the
most effective way to enhance the success of oncolytic virotherapy. However, the
potential benefit of using these two strategies in synergy is promising.
Finally, our results fuel the debate on apparently disparate strategies to enhance
oncolytic virotherapy: develop oncolytic viruses competent to either re-stimulate
antitumoral immune response or inactivate antiviral immunity. Both are currently
under experimental test [38, 46, 47]. Given the complexity of tumor-stroma-immune
system interactions, mathematical modeling can help us to evaluate quantitatively
these strategies or even the result of their combination.
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Appendix A. Parameter estimates
The model parameters determining the cancer growth were fixed at α = 1/L, L = 500,
λ1 = 25, λ2 = 10, θdiv = 0.3, θmov = 5, θdel = 0.03 in order to generate compact, solid
tumors [19]. In all the simulations, the virus parameters were fixed in Tl = 16 time
steps (∼ 64 h), θinf = 0.01, MOI = 3, k = 3, bs = 100, ξ = 0.5, and q = 4. Also,
γv = 0.03 was used, resulting in a clearance rate of 7.5 × 10−3h−1, or only 30% of
its typical value [9]. This value corresponds to a weak innate immune response. The
virotherapy begins when the tumor contains N0 = 5, 000 cancer cells.
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Estimates for the values of the parameters associated to the humoral and cellular
immune response are shown in Table A1. They were used either to guide the choice or
to determine the range of the model parameters used in the simulations as described
next.
Table A1. Typical parameters characterizing the adaptive immune response.
Abbreviation: Ab − antibody.
Parameter Range of values Description Ref.
TB < 8 weeks B cells’ lifespan [28]
TT 4− 8 weeks CD8+ T cells’ lifespan [28]
βB 1.25− 10 h−1 - B cells recruitment rate [36]
βT 1.25− 10 h−1 CD8+ T cells recruitment rate [36]
v 8± 3µm/min CD8+ T cells speed within a tumor [27]
βA 6.944× 10−13g/ml/s Ab secretion rate [48]
A0 2.5× 10−9g/ml Ab concentration at the capillary [28]
γA 2.31× 10−7s−1 Ab clearance rate [49]
DA 10
−8 − 10−7cm2/s Ab diffusion constant [50]
The antibody concentration needed to inactivate a virus was assumed to be
Ainact = 1.25 × 10−6g/ml; the life times of the lymphocytes were fixed in TB =
TT = 200 time steps, corresponding approximately to 5 weeks; the probability of
CD8+-mediated infected cell apoptosis was Papop = 90%; and the minimum number
of infected cells needed to activate an immune response was assumed to be Nmininf = 20.
Nakanishi et al. [36] analyzed the CD8+ T cells entry into into HSV-infected
vaginal tissue and their results indicate that these lymphocytes are recruited at a rate
of 2.5 cells/h. So, in the model the βB and βT values are in the range between 1.25h
−1
and 10h−1. Considering the mean speed of CD8+ T cells migrating within a solid
tumor, a length step of 10µm (the lattice constant), and a simulation time step of
∆t = 4h, lower and upper bounds for the CD8+ surveillance radius can be estimated.
These bounds are given by the mean squared distance traversed by a T cell following
a random and a ballistic trajectory, respectively. For the last case, this distance is
essentially d = vt = 1920µm= 192∆, correspondent to 192 steps and to a upper bound
RT = 192∆. Instead, assuming a random walk with the same number N of steps and
that d =
√〈x2〉 ∼ √N , a lower bound RT ≈ 13∆ is found. Accordingly, the CD8+
T cells surveillance radius RT ranged from 10∆ to 200∆ in simulations. Also, since
each T cell has only 50% of chance to migrate at each time step whereas B cells surely
move, it was assumed RB = RT /2 in order to both lymphocytes exhibit roughly the
same mean speed.
Finally, the diffusion equation for the antibodies, Eq. 9, can be written in a
dimensionless form by performing the variable transformation
t′ =
DAt
∆2
;x′ =
x
∆
;A′ =
A
A0
. (A1)
After some algebraic manipulation, one obtains the equation
∂A′
∂t′
= ∇2A′ + β′AσB − γ′AA′, (A2)
subjected to the boundary condition at the capillary vessel
A′(x, 0) = 1, (A3)
Multiscale model for the effects of adaptive immunity on virotherapy 13
and involving the dimensionless rates of antibodies synthesis and clearance
β′A =
∆2βA
DAA0
; γ′A =
∆2γA
DA
. (A4)
Using the experimental values shown in Table A1, such dimensionless rates were varied
within the ranges β′A ∈ [3 × 10−6, 3 × 10−2] and γ′A ∈ [2.3 × 10−6, 2.3 × 10−5] in
the simulations. In contrast to the nutrient equations that are solved at the quasi-
stationary state, Eq. 9 is iterated for a defined number of times, since the antibodies
diffusion constant can be as small as 10−7.5cm2/s in tissues [50], whereas glucose and
oxygen diffusivities are 10−5cm2/s in tumor spheroids [51].
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